Mercer Global Advisors
MNPR icon

Mercer Global Advisors’s Monopar Therapeutics MNPR Stock Holding History

Mercer Global Advisors’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.33K Buy
+36
New +$2.23K ﹤0.01% 5470

Other funds holding MNPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Mercer Global Advisors's MNPR Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Monopar Therapeutics (MNPR) in Q2 2026: 36 shares worth $3.33K. The stake represents ﹤0.01% of the portfolio and ranks #5470 among its holdings.

51 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Mercer Global Advisors held 36 shares of Monopar Therapeutics worth $3.33K as of Q2 2026.
  • Monopar Therapeutics was a new Mercer Global Advisors position in Q2 2026.
  • Monopar Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #5470 holding.
  • 51 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.